Aptamer's Optimer technology achieves key milestones in genetic medicine delivery, enhancing targeting specificity and ...

A genetic medicines customer has selected the company’s binders for commercial development of the customer’s product. Aptamer Group announced on Nov. 7, 2024 that one of its customers has advanced use ...

York-based biotech firm Aptamer Group has secured new contracts worth almost £500,000 with leading pharmaceutical companies.

Zentek, through its wholly-owned subsidiary Triera Biosciences Ltd., has a global exclusive license to the aptamer-based platform technology developed by McMaster University, which is being jointly ...

York biotech firm, Aptamer Group, has secured new contracts worth up to £471,000. In a commercial trading update the company reports it is "continuing the positive commercial traction" of the past ...

Aptamer Group, a developer of novel Optimer® binders to enable innovation in the life sciences industry, says it has extended ...

Life sciences business, Aptamer Group, has secured new contracts worth up to £471,000. Delivering an update an update on ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday.

Study finds mosaicism in Down syndrome reduces Alzheimer's risk, providing new insights into genetic influences on cognitive ...

Today, Sumsub, a leading full-cycle verification platform, releases the Global Fraud Index, the first-ever in-depth study of 103 countries that offers a complete overview of the risk of digital fraud.

The authors have used this aptamer trigger concept to specifically discriminate ATP from GTP. Pierce remarks, “If we succeed in developing a general aptamer triggering mechanism, then HCR ...

This important manuscript provides insights into the competition between Splicing Factor 1 (SF1) and Quaking (QKI) for binding at the ACUAA branch point sequence in a model intron, regulating exon ...